VolitionRx’s (VNRX) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of VolitionRx (NYSE:VNRX) in a report issued on Tuesday morning,Benzinga reports. They currently have a $5.00 target price on the stock.

VNRX has been the topic of several other research reports. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. StockNews.com initiated coverage on shares of VolitionRx in a research report on Tuesday. They set a “sell” rating on the stock.

VolitionRx Stock Performance

VNRX stock opened at $0.62 on Tuesday. The firm has a market cap of $57.45 million, a PE ratio of -1.72 and a beta of 1.20. The firm’s 50 day moving average price is $0.61 and its 200-day moving average price is $0.65. VolitionRx has a one year low of $0.43 and a one year high of $1.10.

Insider Buying and Selling at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes purchased 174,764 shares of the company’s stock in a transaction on Monday, December 9th. The stock was acquired at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the purchase, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. The trade was a 39.51 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Cameron John Reynolds purchased 139,811 shares of the company’s stock in a transaction on Monday, December 9th. The stock was acquired at an average price of $0.57 per share, with a total value of $79,692.27. Following the purchase, the chief executive officer now owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 358,266 shares of company stock valued at $204,212 over the last quarter. 12.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On VolitionRx

A number of institutional investors and hedge funds have recently modified their holdings of VNRX. Lagoda Investment Management L.P. grew its stake in shares of VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares in the last quarter. Millennium Management LLC acquired a new position in shares of VolitionRx during the fourth quarter worth $36,000. Two Sigma Securities LLC acquired a new position in shares of VolitionRx during the fourth quarter worth $29,000. Finally, Northern Trust Corp grew its stake in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares in the last quarter. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.